Published in:
Open Access
01-11-2013 | Meeting abstract
OR14-002 - ANTI IL-1 therapies and pregnancy outcome
Authors:
HJ Lachmann, H Ozdogan, A Simon, N Stewart, DM Rowczenio, S Ugurlu, T Lane, PN Hawkins
Published in:
Pediatric Rheumatology
|
Special Issue 1/2013
Login to get access
Excerpt
Young women with autoinflammatory diseases on long term IL-1 blockade are increasingly asking about the feasibility, safety and outcomes of pregnancy but few data are available. The FDA classes anakinra as pregnancy risk grade B and rilonacept and canakinumab as grade C. The manufacturers advise that there are no data on the outcome of pregnancy or on excretion into breast milk and that anakinra and canakinumab should only be taken if the benefits outweigh risk; for rilonacept the advice is to avoid in pregnancy. The literature contains only 3 reported cases of use of anakinra in pregnancy – all in adult onset Stills disease (AOSD) and with successful outcomes. …
